


Application Serial No. 10/037,003
Reply to Office Action of June 3, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (withdrawn) A method for providing a source of d4T having an extended half-life in a mammal by administering an effective amount of a compound of Formula I:




Formula I

where R₁ is an aryl group substituted with an electron withdrawing group and R₂ is an amino acid residue or an ester of the amino acid residue, or a pharmaceutically acceptable salt thereof.

2. (withdrawn) The method of claim 1, wherein the aryl group is selected from the group consisting of phenyl, naphthyl, and anthryl.
3. (withdrawn) The method of claim 1, wherein the aryl group is phenyl.
4. (withdrawn) The method of claim 1, wherein the electron-withdrawing group is halo.
5. (withdrawn) The method of claim 1, wherein R₁ is para-bromophenyl.
6. (withdrawn) The method of claim 1, wherein R₂ is an α -amino acid or ester thereof.

Application Serial No. 10/037,003
Reply to Office Action of June 3, 2003

7. (withdrawn) The method of claim 1, wherein R_2 is $-\text{NHCH}(\text{CH}_3)\text{COOCH}_3$.
8. (withdrawn) The method of claim 1, wherein R_1 is para-bromophenyl and R_2 is $-\text{NHCH}(\text{CH}_3)\text{COOCH}_3$.
9. (canceled)
10. (withdrawn) A method for providing a source of d4T having an extended half-life in a mammal by administering an effective amount of a compound of Formula IV:




Formula IV

where R_2 is an amino acid residue or an ester of the amino acid residue, or a pharmaceutically acceptable salt thereof.

11. (withdrawn) The method of claim 10, wherein R_2 is an α -amino acid or ester.
12. (withdrawn) The method of claim 10, wherein R_2 is $-\text{NHCH}(\text{CH}_3)\text{COOCH}_3$.
13. (canceled)
14. (currently amended) A method for extending the half-life of a compound of formula I in a mammal comprising administering to the mammal:

Application Serial No. 10/037,003
Reply to Office Action of June 3, 2003

an esterase inhibitor, wherein the esterase inhibitor is a cholinesterase inhibitor, carboxylesterase inhibitor, or a combination of cholinesterase and carboxylesterase inhibitors;
and
a compound of formula I;
wherein the compound of formula I is:



where R₁ is an aryl group substituted with an electron withdrawing group and R₂ is an amino acid residue or an ester of the amino acid residue, or a pharmaceutically acceptable salt thereof.


15. (previously presented) The method of claim 14, wherein the aryl group is selected from the group consisting of phenyl, naphthyl, and anthryl.
16. (previously presented) The method of claim 14, wherein the aryl group is phenyl.
17. (previously presented) The method of claim 14, wherein the electron-withdrawing group is halo.
18. (previously presented) The method of claim 14, wherein R₁ is para-bromophenyl.
19. (previously presented) The method of claim 14, wherein R₂ is an α -amino acid or ester thereof.

Application Serial No. 10/037,003
Reply to Office Action of June 3, 2003

20. (previously presented) The method of claim 14, wherein R_2 is $-\text{NHCH}(\text{CH}_3)\text{COOCH}_3$.
21. (previously presented) The method of claim 14, wherein R_1 is para-bromophenyl and R_2 is $-\text{NHCH}(\text{CH}_3)\text{COOCH}_3$.
22. (currently amended) The method of claim 14, wherein the compound of formula I is administered intravenously.
23. (previously presented) The method of claim 14, wherein the compound of formula I is administered orally.
24. (canceled)
25. (currently amended) The method of claim ~~24~~14, wherein the inhibitor of cholinesterase is paraoxon.
26. (currently amended) The method of claim ~~24~~14, wherein the inhibitor of cholinesterase is physostigmine.
27. (currently amended) The method of claim 21, wherein the inhibitor of cholinesterase is selected from paraoxon and physostigmine.
28. (previously presented) The method of claim 14, wherein the compound of formula I and the esterase inhibitor are administered concurrently.
29. (previously presented) The method of claim 14, wherein the compound of formula I and the esterase inhibitor are administered in a single dosage form.
30. (previously presented) The method of claim 29, wherein the a single dosage form is a parenteral dosage form.

Application Serial No. 10/037,003
Reply to Office Action of June 3, 2003

31. (withdrawn) A pharmaceutical composition comprising:
an esterase inhibitor; and
a compound of formula I:



(I)

where R₁ is an aryl group substituted with an electron withdrawing group and R₂ is an amino acid residue or an ester of the amino acid residue, or a pharmaceutically acceptable salt thereof; the method; and
a pharmaceutically acceptable carrier or diluent.

32. (withdrawn) The composition of claim 31, wherein the aryl group is selected from the group consisting of phenyl, naphthyl, and anthryl.
33. (withdrawn) The composition of claim 31, wherein the aryl group is phenyl.
34. (withdrawn) The composition of claim 31, wherein the electron-withdrawing group is halo.
35. (withdrawn) The composition of claim 31, wherein R₁ is para-bromophenyl.
36. (withdrawn) The composition of claim 31, wherein R₂ is an α -amino acid or ester thereof.

Application Serial No. 10/037,003
Reply to Office Action of June 3, 2003

37. (withdrawn) The composition of claim 31, wherein R_2 is $-\text{NHCH}(\text{CH}_3)\text{COOCH}_3$.
38. (withdrawn) The composition of claim 31, wherein R_1 is para-bromophenyl and R_2 is $-\text{NHCH}(\text{CH}_3)\text{COOCH}_3$.
39. (withdrawn) The composition of claim 31, wherein the esterase inhibitor is selected from the group of an inhibitor of cholinesterase, an inhibitor of carboxylesterase, or a combination thereof.
40. (withdrawn) The composition of claim 39, wherein the inhibitor of cholinesterase is paraoxon.
41. (withdrawn) The composition of claim 39, wherein the inhibitor of cholinesterase is phyostigmine.
42. (withdrawn) The composition of claim 38, wherein the inhibitor of cholinesterase is selected from paraoxon and phyostigmine.
43. (withdrawn) The composition of claim 31, wherein the composition is adapted for intravenous administration.
44. (withdrawn) The composition of claim 31, wherein the composition is adapted for intravenous administration.
45. (new) The method of claim 14, wherein the inhibitor of carboxylesterase is paraoxon.